Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60

Benzinga · 1d ago
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $78 to $60.